The key differences are dose and FDA-approved indication: Key Takeaway on Ozempic vs Wegovy If your goal is weight loss and you do not have type 2 diabetes, Wegovy is the on-label, insurance-supported choice when semaglutide is indicated

More serious but less common adverse effects require clinical vigilance: Pancreatitis : Patients should be counselled to stop the medication and seek immediate medical attention if they experience severe, persistent abdominal pain radiating to the back [1] [5] Gallbladder disease : Rapid weight loss associated with GLP-1 therapy may increase cholelithiasis risk [1] Hypoglycaemia : Particularly when used alongside insulin or sulphonylureas in diabetes management Diabetic retinopathy : Semaglutide requires caution in patients with pre-existing retinopathy, who should be monitored regularly [1] Renal impairment : Dehydration from gastrointestinal side effects may affect kidney function Specific considerations for individuals with eating disorders include the potential for GLP-1 medications to exacerbate restrictive eating patterns or mask hunger cues in vulnerable individuals

2 Substance evaluation cases agreed in advance (written procedure) MSC had already agreed several draft decisions under written procedure, including the following substances: Bis(2-propylheptyl) phthalate (EC 258-469-4) 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthyl)ethan-1-one (EC 216-133-4) 2-Propenoic acid, methyl ester, reaction products with mixed O,O-bis(branched and linear pentyl and iso-Bu) phosphorodithioates (EC 300-340-2) 4,4'-isopropylidenebis[2-allylphenol] (EC 217-121-1) 3 Dossier evaluation decisions also progressed Under dossier evaluation, MSC agreed cases including: Amines, C36-alkylenedi- (EC 273-282-8) Pivalic acid (EC 200-922-5) (Plus one compliance check case listed as confidential.) 4 Ad hoc Working Group established on SVHC ELoC cases (Art
Rapid injection sometimes causes temporary stinging
Medicaid coverage for GLP-1 drugs varies depending on the state